Preliminary results from a randomized, open-label, phase 2 study of botensilimab (BOT) with or without balstilimab (BAL) in refractory microsatellite stable metastatic colorectal cancer with no liver metastases (MSS mCRC NLM).

Details

Language :

English

ISSN :

0732183X

Volume :

43

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

182478930

Full Text :

https://doi.org/10.1200/JCO.2025.43.4_suppl.23